Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis(Front. Immunol., (2022), 13, (935700), 10.3389/fimmu.2022.935700)

Yun Ju Huang; Chiung Hung Lin; Huang Yu Yang; Shue-Feng Luo; Chang Fu Kuo

doi:10.3389/fimmu.2022.1003761

Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis(Front. Immunol., (2022), 13, (935700), 10.3389/fimmu.2022.935700)

Yun Ju Huang
, Chiung Hung Lin
, Huang Yu Yang
, Shue-Feng Luo
, Chang Fu Kuo^*

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Abstract

In the published article, there was an error in Figure 2 as published. We mistakenly used the Figure 1 as Figure 2. The Figure 1 describes us CD163 in urine and SLEDA4I-2K in SLE patients while the Figure 2. describes usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The corrected Figure 2 and its caption appear below. In the published article, there was an error in the Funding statement. Funding from Chang Gung Memorial Hospital Research Program (CMRPG3J0031) was omitted. The correct Funding statement appears below.

Original language	English
Article number	1003761
Journal	Frontiers in Immunology
Volume	13
DOIs	https://doi.org/10.3389/fimmu.2022.1003761
State	Published - 29 08 2022

Bibliographical note

Publisher Copyright:
© 2022 Huang, Lin, Yang, Luo and Kuo.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

SLEDA
Systemic lupus erythematosus
chronic kidney disease
lupus nephritis
macrophage
urine biomarker
urine soluble CD163

Access to Document

10.3389/fimmu.2022.1003761

Cite this

@article{fa59e3fb9eaa48478e5a1fc7923a879b,

title = "Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis(Front. Immunol., (2022), 13, (935700), 10.3389/fimmu.2022.935700)",

abstract = "In the published article, there was an error in Figure 2 as published. We mistakenly used the Figure 1 as Figure 2. The Figure 1 describes us CD163 in urine and SLEDA4I-2K in SLE patients while the Figure 2. describes usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The corrected Figure 2 and its caption appear below. In the published article, there was an error in the Funding statement. Funding from Chang Gung Memorial Hospital Research Program (CMRPG3J0031) was omitted. The correct Funding statement appears below.",

keywords = "SLEDA, Systemic lupus erythematosus, chronic kidney disease, lupus nephritis, macrophage, urine biomarker, urine soluble CD163",

author = "Huang, \{Yun Ju\} and Lin, \{Chiung Hung\} and Yang, \{Huang Yu\} and Shue-Feng Luo and Kuo, \{Chang Fu\}",

note = "Publisher Copyright: {\textcopyright} 2022 Huang, Lin, Yang, Luo and Kuo.",

year = "2022",

month = aug,

day = "29",

doi = "10.3389/fimmu.2022.1003761",

language = "英语",

volume = "13",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Corrigendum

T2 - Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis(Front. Immunol., (2022), 13, (935700), 10.3389/fimmu.2022.935700)

AU - Huang, Yun Ju

AU - Lin, Chiung Hung

AU - Yang, Huang Yu

AU - Luo, Shue-Feng

AU - Kuo, Chang Fu

PY - 2022/8/29

Y1 - 2022/8/29

N2 - In the published article, there was an error in Figure 2 as published. We mistakenly used the Figure 1 as Figure 2. The Figure 1 describes us CD163 in urine and SLEDA4I-2K in SLE patients while the Figure 2. describes usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The corrected Figure 2 and its caption appear below. In the published article, there was an error in the Funding statement. Funding from Chang Gung Memorial Hospital Research Program (CMRPG3J0031) was omitted. The correct Funding statement appears below.

AB - In the published article, there was an error in Figure 2 as published. We mistakenly used the Figure 1 as Figure 2. The Figure 1 describes us CD163 in urine and SLEDA4I-2K in SLE patients while the Figure 2. describes usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The corrected Figure 2 and its caption appear below. In the published article, there was an error in the Funding statement. Funding from Chang Gung Memorial Hospital Research Program (CMRPG3J0031) was omitted. The correct Funding statement appears below.

KW - SLEDA

KW - Systemic lupus erythematosus

KW - chronic kidney disease

KW - lupus nephritis

KW - macrophage

KW - urine biomarker

KW - urine soluble CD163

UR - https://www.scopus.com/pages/publications/85138267572

U2 - 10.3389/fimmu.2022.1003761

DO - 10.3389/fimmu.2022.1003761

M3 - 评论/辩论

C2 - 36105812

AN - SCOPUS:85138267572

SN - 1664-3224

VL - 13

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 1003761

ER -

Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis(Front. Immunol., (2022), 13, (935700), 10.3389/fimmu.2022.935700)

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this